from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A novel small-molecular agent designed to make ribosomes become less sensitive to, or possibly ignore, premature stop codons.


Sorry, no etymologies found.


Help support Wordnik (and make this page ad-free) by adopting the word ataluren.


  • PTC Therapeutics, a 13-year-old biotech that has received $100 million from Genzyme, is conducting a phase III trial of its compound, ataluren, in cystic fibrosis patients with a so-called nonsense mutation.

    Gene Discovery Was Only First Step Jonathan D. Rockoff 2011

  • The UAB study showed that ataluren allowed the protein to be made in mouse cells where it was previously absent, and it helped the body's regulatory system to restore salt and water balance in the membrane.

    News for 2010

  • Another researcher not affiliated with UAB has reported ataluren restored up to 25 percent of the missing or abnormal protein function in mice with Duchenne muscular dystrophy.

    News for 2010

  • In Bedwell's most well-known study, ataluren restored up to 29 percent of normal protein function in mice with cystic fibrosis.

    News for 2010

  • Finally, just to reinforce Henri's comment that we do expect to see top line data from the registration trial for ataluren in nonsense-mutation Duchenne Muscular Dystrophy in the first half. Home Page 2010

  • Results of a pivotal phase 2b trial of ataluren in Duchenne Eliminating cancer stem cells (CSCs) within a tumor could hold the key to successful treatments for ...

    THE MEDICAL NEWS Editors 2010

  • This drug ataluren (formerly called PTC124) also holds promise in treating more than 2,400 different genetic disorders caused by nonsense mutations.

    News for 2010

  • Genzyme is collaborating with PTC Therapeutics Inc. on ataluren, a novel oral therapy for the treatment of genetic disorders due to nonsense mutations.

    THE MEDICAL NEWS Editors 2010

  • A pivotal phase 2b trial of ataluren in Duchenne muscular dystrophy is fully enrolled and results are anticipated in the first half of next year. Featured News and Stories 2009

  • PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124 (R)) in Patients with Hemophilia for releases, photos, ProfNet experts, and customized feeds just for Media.

    unknown title 2009


Log in or sign up to get involved in the conversation. It's quick and easy.